Intuitive Surgical, Inc. $ISRG Stock: SteelPeak Wealth LLC Trims Stake

Key Points

• SteelPeak Wealth LLC cut its Intuitive Surgical stake by 68% in the third quarter, selling 26,645 shares and retaining 12,535 shares worth approximately $5.1 million.
• Institutional investors own 83.64% of ISRG, while several major funds—including Bank of America, Amundi and Arrowstreet Capital—expanded their positions.
• Intuitive Surgical continues to post strong operating growth, with quarterly revenue up 18.4% and earnings exceeding estimates, but analysts cite slowing U.S. procedure growth, China-related headwinds and a premium valuation as risks. The stock has a “Moderate Buy” consensus rating with an average price target of $498.83.

SteelPeak Wealth LLC reduced its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 68.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 12,535 shares of the medical equipment provider's stock after selling 26,645 shares during the quarter. SteelPeak Wealth LLC's holdings in Intuitive Surgical were worth $5,097,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of ISRG. Bank of America Corp DE increased its holdings in Intuitive Surgical by 3.3% during the 1st quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider's stock worth $1,667,388,000 after purchasing an additional 116,292 shares during the period. Bank of New York Mellon Corp purchased a new position in shares of Intuitive Surgical in the 2nd quarter worth approximately $1,335,753,000. Amundi grew its holdings in Intuitive Surgical by 8.6% in the first quarter. Amundi now owns 2,428,356 shares of the medical equipment provider's stock worth $1,119,448,000 after purchasing an additional 193,096 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Intuitive Surgical by 95.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider's stock valued at $970,635,000 after purchasing an additional 1,027,475 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in Intuitive Surgical by 13.8% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,745,008 shares of the medical equipment provider's stock worth $804,431,000 after acquiring an additional 211,237 shares during the period. Institutional investors own 83.64% of the company's stock.

More Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Analysts at Erste Group Bank raised their earnings estimates for ISRG, suggesting improved expectations for the company’s upcoming results and longer-term profitability. Erste Group Bank Analysts Boost Earnings Estimates for ISRG
• Positive Sentiment: Recent results have shown double-digit growth in robotic-surgery procedures, revenue and Intuitive Surgical’s installed base of systems. That underlying operating momentum remains a key support for the investment case despite the stock’s broader underperformance this year. Intuitive Surgical Valuation and Growth
• Positive Sentiment: The shares increased in the prior session and outperformed the broader market that day, reflecting some investor support ahead of the earnings release. ISRG Beats Stock Market Upswing
• Neutral Sentiment: Investors are focused on third-quarter procedure growth, da Vinci system demand, revenue, margins and other operating metrics—not just earnings per share and revenue—to determine whether recent momentum is sustainable. ISRG Ahead of Q3 Earnings
• Negative Sentiment: Expectations are tempered by slowing U.S. procedure growth and headwinds in China. These issues could pressure system placements and margins, increasing the risk of an earnings-related market reaction. ISRG Q3 Earnings Preview
• Negative Sentiment: Despite double-digit growth, shares have declined substantially during 2026 and trade at a premium valuation. Investors are questioning whether a valuation around 33 times expected earnings adequately reflects the company’s growth prospects, particularly if procedure growth slows. ISRG Valuation Analysis

Intuitive Surgical Stock Performance

Shares of ISRG opened at $426.70 on Friday. The stock has a 50-day simple moving average of $391.43 and a 200-day simple moving average of $409.74. The stock has a market capitalization of $150.74 billion, a PE ratio of 48.88, a PEG ratio of 3.22 and a beta of 1.46. Intuitive Surgical, Inc. has a 1 year low of $328.57 and a 1 year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 EPS for the quarter, beating the consensus estimate of $2.48 by $0.32. The firm had revenue of $2.89 billion for the quarter, compared to analyst estimates of $2.83 billion. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%. Intuitive Surgical's revenue for the quarter was up 18.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.81 earnings per share. Analysts predict that Intuitive Surgical, Inc. will post 8.87 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on ISRG shares. TD Cowen cut shares of Intuitive Surgical from a "buy" rating to a "hold" rating in a report on Tuesday, July 28th. Leerink Partners reduced their target price on shares of Intuitive Surgical from $573.00 to $454.00 and set an "outperform" rating for the company in a research report on Friday, July 17th. Robert W. Baird lowered their price objective on Intuitive Surgical from $525.00 to $500.00 and set an "outperform" rating on the stock in a research note on Friday, July 17th. Citigroup reduced their price target on shares of Intuitive Surgical from $590.00 to $500.00 and set a "buy" rating on the stock in a research report on Friday, July 17th. Finally, Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Intuitive Surgical in a research report on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $498.83.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Mark Brosius sold 77 shares of the firm's stock in a transaction on Friday, August 21st. The shares were sold at an average price of $375.57, for a total transaction of $28,918.89. Following the transaction, the executive vice president directly owned 881 shares of the company's stock, valued at approximately $330,877.17. This trade represents a 8.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Fredrik Widman sold 1,089 shares of the business's stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $374.44, for a total value of $407,765.16. Following the completion of the transaction, the vice president directly owned 1,026 shares in the company, valued at approximately $384,175.44. The trade was a 51.49% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 12,370 shares of company stock worth $4,891,989. Corporate insiders own 0.60% of the company's stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company's primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.

Want to see what other hedge funds are holding ISRG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.